292 related articles for article (PubMed ID: 35223745)
1. Targeting TNF-α for COVID-19: Recent Advanced and Controversies.
Guo Y; Hu K; Li Y; Lu C; Ling K; Cai C; Wang W; Ye D
Front Public Health; 2022; 10():833967. PubMed ID: 35223745
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19).
Norooznezhad AH; Mansouri K
Microvasc Res; 2021 Sep; 137():104188. PubMed ID: 34022205
[TBL] [Abstract][Full Text] [Related]
3. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages.
Pantazi I; Al-Qahtani AA; Alhamlan FS; Alothaid H; Matou-Nasri S; Sourvinos G; Vergadi E; Tsatsanis C
Front Immunol; 2021; 12():683800. PubMed ID: 34248968
[TBL] [Abstract][Full Text] [Related]
5. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
Moradian N; Gouravani M; Salehi MA; Heidari A; Shafeghat M; Hamblin MR; Rezaei N
Eur Cytokine Netw; 2020 Sep; 31(3):81-93. PubMed ID: 33361013
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 infection: an overview on cytokine storm and related interventions.
Montazersaheb S; Hosseiniyan Khatibi SM; Hejazi MS; Tarhriz V; Farjami A; Ghasemian Sorbeni F; Farahzadi R; Ghasemnejad T
Virol J; 2022 May; 19(1):92. PubMed ID: 35619180
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.
Que Y; Hu C; Wan K; Hu P; Wang R; Luo J; Li T; Ping R; Hu Q; Sun Y; Wu X; Tu L; Du Y; Chang C; Xu G
Int Rev Immunol; 2022; 41(2):217-230. PubMed ID: 33616462
[TBL] [Abstract][Full Text] [Related]
8. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model.
Gu T; Zhao S; Jin G; Song M; Zhi Y; Zhao R; Ma F; Zheng Y; Wang K; Liu H; Xin M; Han W; Li X; Dong CD; Liu K; Dong Z
Front Immunol; 2020; 11():621441. PubMed ID: 33584719
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal M2 macrophage-derived extracellular vesicles as natural multitarget nanotherapeutics to attenuate cytokine storms after severe infections.
Wang Y; Liu S; Li L; Li L; Zhou X; Wan M; Lou P; Zhao M; Lv K; Yuan Y; Chen Y; Lu Y; Cheng J; Liu J
J Control Release; 2022 Sep; 349():118-132. PubMed ID: 35792186
[TBL] [Abstract][Full Text] [Related]
10. Interplay of Opposing Effects of the WNT/β-Catenin Pathway and PPARγ and Implications for SARS-CoV2 Treatment.
Vallée A; Lecarpentier Y; Vallée JN
Front Immunol; 2021; 12():666693. PubMed ID: 33927728
[TBL] [Abstract][Full Text] [Related]
11. The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.
Ayola-Serrano NC; Roy N; Fathah Z; Anwar MM; Singh B; Ammar N; Sah R; Elba A; Utt RS; Pecho-Silva S; Rodriguez-Morales AJ; Dhama K; Quraishi S
Inflamm Res; 2021 Aug; 70(8):877-889. PubMed ID: 34086061
[TBL] [Abstract][Full Text] [Related]
12. Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes.
Lee CY; Huang CH; Rastegari E; Rengganaten V; Liu PC; Tsai PH; Chin YF; Wu JR; Chiou SH; Teng YC; Lee CW; Liang Y; Chen AY; Hsu SC; Hung YJ; Sun JR; Chien CS; Chien Y
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576032
[TBL] [Abstract][Full Text] [Related]
13. Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
León FJF; da Silva LL; Santos AC; Duarte da Costa V; Miguel JC; Marques JT; Nascimento GP; Ferreira da Silva E; Lewis-Ximenez LL; Villar LM; de Paula VS
J Med Virol; 2022 May; 94(5):2296-2301. PubMed ID: 35064576
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
Azar MM; Shin JJ; Kang I; Landry M
Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
[TBL] [Abstract][Full Text] [Related]
15. Prolonged NHE Activation may be both Cause and Outcome of Cytokine Release Syndrome in COVID-19.
Cure MC; Cure E
Curr Pharm Des; 2022; 28(22):1815-1822. PubMed ID: 35838211
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-α agents Modulate SARS-CoV-2 Receptors and Increase the Risk of Infection Through Notch-1 Signaling.
Keewan E; Beg S; Naser SA
Front Immunol; 2021; 12():641295. PubMed ID: 34025650
[TBL] [Abstract][Full Text] [Related]
17. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19.
Mostafa-Hedeab G; Al-Kuraishy HM; Al-Gareeb AI; Jeandet P; Saad HM; Batiha GE
Inflammopharmacology; 2022 Jun; 30(3):799-809. PubMed ID: 35486310
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Effects of Curcumin on the Cytokine Storm in COVID-19 Using a Chip-Based Multiplex Analysis.
Zahedipour F; Guest PC; Majeed M; Moallem SA; Kesharwani P; Jamialahmadi T; Sahebkar A
Methods Mol Biol; 2022; 2511():285-295. PubMed ID: 35838968
[TBL] [Abstract][Full Text] [Related]
20. Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab.
Dolinger MT; Person H; Smith R; Jarchin L; Pittman N; Dubinsky MC; Lai J
J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):153-155. PubMed ID: 32452979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
